Bayer HealthCare

Employees 2013: 56,000
Employees 2012: 55,300
% change: +1.27
Revenues 2013: $25.97 billion
Revenues per employee: $463,732

In many ways last year was pretty static for Bayer HealthCare, the healthcare unit of Bayer Group that makes up about half the conglomerate's revenues.

It saw some nice growth in its pharmaceuticals, 9.4%, reaching €11.2 billion. Drugs like its blood thinner Xarelto and eye med Eylea were key, helped by cancer therapies Stivarga and Xofigo and pulmonary hypertension treatment Adempas; together, they posted €1.5 billion in 2013 sales.

But pharma is only one piece of the whole, which also includes its consumer healthcare, medical devices and animal health units. So revenues for that whole ended up about 1.7% for the year and employment grew by 1.3%. It remained near the bottom, seventh, in terms of revenues per employee. Like I said, static.

That is not to say that there were not some notable events. A new leader was named for the unit. Bayer Group CEO Marijn Dekkers tapped a 57-year-old former Pfizer ($PFE) executive, Dr. Olivier Brandicourt, to run things. Early last year, it added birth control device maker Conceptus ($CPTS) in a $1.1 billion acquisition to provide some help in its birth control division, where drugs like Yaz have seen sales fall. Then at the end of last year, it plopped down nearly $3 billion to pick up Algeta, the Norwegian drugmaker that's also its partner on the aforementioned Xofigo cancer treatment. Those two moves added about 460 employees.

But the potential big mover for Bayer in terms of adding both revenues and people to the healthcare engine came this year when it agreed to buy Merck's ($MRK) consumer health unit in a $14.2 billion deal. The unit did $2.2 billion in sales last year and has about 2,250 employees. Of course, how many of those end up on the Bayer payroll is yet to be known.

For more:
Dekkers says Bayer may add to animal health division with M&A, in time
Bayer aims to crush consumer health rivals with $14B Merck unit buyout
With Big 5, Bayer aims for 8% annual pharma growth through 2016
With a sweetened $2.9B bid, Bayer nabs its Xofigo partner, Algeta
Germany's Bayer taps Pfizer's Olivier Brandicourt to head Bayer HealthCare
Bayer bolsters birth-control business with $1.1B Conceptus buyout

Bayer HealthCare
Read more on

Suggested Articles

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.